Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study

In the Asia‐Pacific region, treatment options are limited for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Rituximab is widely used in this setting when purine analog‐based therapies are not appropriate. We evaluated the efficacy and safety o...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiaojun, Qiu, Lugui, Jin, Jie, Zhou, Daobin, Chen, Xiequn, Hou, Ming, Hu, Jianda, Hu, Yu, Ke, Xiaoyan, Li, Junmin, Liang, Yingmin, Liu, Ting, Lv, Yue, Ren, Hanyun, Sun, Aining, Wang, Jianmin, Zhao, Chunting, Salman, Mariya, Sun, Steven, Howes, Angela, Wang, Jingzhao, Wu, Peng, Li, Jianyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911578/
https://www.ncbi.nlm.nih.gov/pubmed/29533000
http://dx.doi.org/10.1002/cam4.1337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911578/
https://www.ncbi.nlm.nih.gov/pubmed/29533000
http://dx.doi.org/10.1002/cam4.1337

Ejemplares similares